《大行报告》摩根士丹利对中资医药股最新评级及目标价(表)
摩根士丹利发表研究报告,对中资医药股最新评级及目标价如下:
股份│投资评级│目标价(港元)
三生制药(01530.HK)│增持│16元→14.5元
康希诺生物(06185.HK)│增持│48元→68元
华润医疗(01515.HK)│增持│7元→5.6元
石药集团(01093.HK)│增持│25元→23.2元
翰森制药(03692.HK)│增持│29元→30.3元
信达生物(01801.HK)│增持│35元→36元
锦欣生殖(01951.HK)│增持│11元→12.5元
李氏大药厂(00950.HK)│与大市同步│4.2元→5元
石四药(02005.HK)│增持│8.5元→8元
药明生物(02269.HK)│增持│94元→124元
药明康德(02359.HK)│增持│87.86元→124元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.